Press Releases

Date	Title and Summary	Additional Formats
Jun 19, 2019	Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research Illuminating the diversity of immune cell phenotypes and function in the context of the tumor microenvironment, all in a single scan SOUTH SAN FRANCISCO, Calif. , June 19, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
Jun 17, 2019	Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif. , June 17, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Jun 04, 2019	Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer SOUTH SAN FRANCISCO, Calif. , June 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Andrew Quong , PhD, has joined the company as its first-ever Chief Science Officer. Quong will lead the company’s strategy for the generation of bold scientific insights in
May 31, 2019	Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. , May 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 31, 2019 , under Fluidigm’s
May 29, 2019	Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research Introducing the most comprehensive commercially available NGS assay for detecting gene fusions in cancer using an automated nanoscale library prep workflow SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider
May 29, 2019	Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology The first commercially available targeted NGS assay that enables simultaneous detection of somatic variants across 53 solid tumor genes using a highly efficient microfluidic library prep workflow SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an
May 10, 2019	Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. , May 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of May 7, 2019 , under Fluidigm’s 2017
May 09, 2019	Fluidigm to Participate in Upcoming Health Care Investor Conferences SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
May 02, 2019	Fluidigm Announces First Quarter 2019 Financial Results First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry instrument adoption First complete sample-to-answer solution for deep immune profiling in mass cytometry SOUTH SAN FRANCISCO,
May 02, 2019	Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging